HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Innovative Approaches in Addiction Treatment: Digital Solutions and New Therapies

Intelligence briefing

Intelligence Briefing · ~5 min read

Innovative Approaches in Addiction Treatment: Digital Solutions and New Therapies

Addiction · Substance Use Disorders

Type

Regulatory Context Briefing

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 72%

Evidence

11 items

Sources

11

Key Takeaways

Leadership-ready summary — read in 5 minutes.

  • Regulatory risk is concentrated around Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings (MHRA). Sponsor/company relevance (Pfizer). While the study may not directly affect regulatory approvals, it could inform future treatment protocols and guidelines for smoking cessation.
  • Regulatory exposure for digital therapeutic solutions may delay market entry or constrain labeling if agency reviews intensify.
  • Elevated medium regulatory exposure for Tirzepatide could impact its approval and labeling if trial outcomes do not meet expectations.

Why It Matters

Strategic context for leadership and portfolio decision-making.

Regulatory risk is concentrated around Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings (MHRA). Sponsor/company relevance (Pfizer). While the study may not directly affect regulatory approvals, it could inform future treatment protocols and guidelines for smoking cessation.

Supporting Evidence

Evidence-backed items from the Humanexa intelligence graph.

  • Study on App-Based Incentives for Older Adults with Substance Use Disorders

    Addiction · Substance Use Disorders

    Source: Trial Update

    View evidence
  • Tirzepatide Evaluated for Cannabis Use Disorder in Proof-of-Concept Study

    Addiction · GLP-1 Receptor Agonist

    Source: Trial Update

    View evidence
  • NIAAA Launches Study on Addictions Neuroclinical Assessment for Alcohol Use Disorder

    Addiction · Alcohol Use Disorder

    Source: Trial Update

    View evidence
  • Feasibility Study on Olfactory Stimuli in VR for Alcohol Dependence Patients

    Addiction · Alcohol Dependence

    Source: Trial Update

    View evidence
  • Pilot Study on Text-Based Contingency Management for Smoking Cessation Engagement

    Addiction · Smoking Cessation

    Source: Trial Update

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Study on App-Based Incentives for Older Adults with Substance Use Disorders

    Addiction · Substance Use Disorders

  • Tirzepatide Evaluated for Cannabis Use Disorder in Proof-of-Concept Study

    Addiction · GLP-1 Receptor Agonist

  • NIAAA Launches Study on Addictions Neuroclinical Assessment for Alcohol Use Disorder

    Addiction · Alcohol Use Disorder

  • Feasibility Study on Olfactory Stimuli in VR for Alcohol Dependence Patients

    Addiction · Alcohol Dependence

  • Pilot Study on Text-Based Contingency Management for Smoking Cessation Engagement

    Addiction · Smoking Cessation

Insights

  • Innovative Approaches in Addiction Treatment: Digital Solutions and New Therapies

    Addiction · Substance Use Disorders

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.